Currently, LNTH's 12-month EPS stands at $4.22, according to the most recent financial reports. During 2025, LNTH reported a per-share earnings of $3.46, which shows a decline compared to the EPS of $4.52 recorded in 2024. LNTH recorded an EPS of $1.83 for the quarterly period ending on Mar 31, 2026.
In 2025, Lantheus Holdings's earnings per share was $3.46, a decline of 23.5% from $4.52 in 2024. Over the quarter ending Mar 31, 2026, the earnings per share came in at $1.83, reflecting a 72.6% increase compared to the same quarter a year earlier. As of March 2026, the TTM EPS is $4.22. During 2024, the annual earnings per share was $4.52, representing a decrease of 5.6% compared to 2023.
Lantheus Holdings has recorded a growth in earnings per share of 72.6% in the past 12 months (YoY, quarterly). During the past three years, LNTH registered an average yearly EPS growth of 103.6%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| LNTH Lantheus Holdings Inc | 24.37 | -23.5% | 103.6% | N/A |
| ABT Abbott Laboratories | 25.24 | -51.4% | -1.8% | 8.2% |
| IDXX Idexx Laboratories Inc | 41.23 | 22.3% | 17.5% | 14.1% |
| CTSO Cytosorbents Corp | N/A | 65.8% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.